View of Economic evaluation of abiraterone acetate for the treatment of metastatic castration-resistant prostate cancer patients previously treated with docetaxel under the Brazilian private healthcare system

Return to Article Details Economic evaluation of abiraterone acetate for the treatment of metastatic castration-resistant prostate cancer patients previously treated with docetaxel under the Brazilian private healthcare system Download Download PDF